Maze Therapeutics

Maze Therapeutics reported at the H.C. Wainwright conference progress on the APOL1 inhibitor MZE829 (Phase II HORIZON) and the PKU candidate MZE782. The company expects final HORIZON data by end‑2024/early‑2025 and plans to launch a registration‑enabling MZE829 program in H1 2025; a Phase II start for MZE782 in CKD is also planned for H1 2025, with top‑line PKU data expected in 2027. Early data show an average UACR reduction of 36% (50% responder rate) for MZE829 and a 42‑fold increase in urinary Phe excretion with MZE782; further development steps will depend largely on upcoming data, biomarker analyses and PARSOL‑Shield recommendations. » Más en de.investing.com

Maze Therapeutics presented early clinical signals at the Citigroup Biopharma Summit: the lead APOL1 program MZE829 showed a mean UACR reduction of 36% in 12 evaluable patients, with particularly strong effects in the FSGS subgroup. The PKU program MZE782 recorded a 42-fold increase in urinary phenylalanine excretion in Phase I and is already in Phase II. Management emphasized that key approval decisions, study-design discussions with the FDA and final HORIZON data are still outstanding; financial figures were not disclosed. » Más en de.investing.com

Maze Therapeutics has appointed Dr. med. Paula Johnson and Dr. pharm. Sophie Kornowski to its board of directors. Johnson brings more than 30 years of experience in clinical cardiology and research as well as leadership roles in academia and oversight bodies; Kornowski has over 35 years of executive experience in the biopharma industry, most recently as CEO of Boston Pharmaceuticals. The clinical biopharma company develops small‑molecule precision medicines for kidney and metabolic diseases and expects additional data on MZE829 in late 2026/early 2027 as well as initial data on MZE782 in 2027. » Más en de.investing.com